If you are wondering whether ImmunityBio’s recent share price makes sense or not, you are not alone; the stock has attracted attention from investors trying to work out what a fair value might look like.
The share price closed at US$2.82, with returns of 31.8% over the last 7 days, 19.5% over the last 30 days and 39.6% year to date, while the 1 year return sits at 21.6% and the 3 year return at negative 40.5%.
Recent news flow around ImmunityBio has focused on its clinical pipeline and regulatory progress, as well as funding and capital position updates that matter for a biotech at this stage. These developments help frame how investors are reacting to the stock’s risk profile and are a useful backdrop when thinking about what the…
